| Web: | mayocliniclabs.com |
|---|---|
| Email: | mcl@mayo.edu |
| Telephone: | 800-533-1710 |
| International: | +1 855-379-3115 |
| Values are valid only on day of printing | |
| Web: | mayocliniclabs.com |
|---|---|
| Email: | mcl@mayo.edu |
| Telephone: | 800-533-1710 |
| International: | +1 855-379-3115 |
| Values are valid only on day of printing | |
A history of innovation and discovery
The Mayo Clinic Neuroimmunology Laboratory was the first to introduce comprehensive serological evaluations for the diagnosis of paraneoplastic neurologic autoimmune disorders, a group of disorders in which unusual neurologic signs and symptoms are the initial manifestations of cancer.
The laboratory continues to discover and clinically validate novel autoantibody profiles that inform neurological decision-making and guide the search for cancer, leading an evolution in autoimmune neurology diagnosis. Powered by expertise from our research labs, clinical labs, and Autoimmune Neurology Clinic, we have developed panels customized to address specific phenotypes. This approach delivers more clinically actionable results, providing a clear picture of the diagnosis, prognosis, and treatment options.
“Clinicians are used to looking for patterns in their clinical work, and we’re transferring that expertise into a clinical laboratory space. That’s not something that you learn overnight — it’s gained with experience over years.”
Andrew McKeon, M.B., B.Ch., M.D.
The latest
What started as a persistent headache for Spencer Lodin soon devolved into slowed speech, seizures, and hallucinations, symptoms which stumped ER doctors into thinking he had meningitis or was suffering from psychosis. Finally, specialized testing at Mayo Clinic identified Spencer's condition as GFAP-IgG associated autoimmune encephalitis, which allowed for targeted treatment and a full recovery.
Mayo Clinic Laboratories has marked a significant advancement in the fight against Alzheimer's disease with the introduction of an innovative diagnostic test. This noninvasive blood test accurately detects the p-Tau217 biomarker, indicative of amyloid beta accumulation in the brain. This test is set to transform the approach to Alzheimer's disease management, offering a convenient and less invasive alternative to traditional diagnostic methods.
Antibody against the GABA-A receptor is a biomarker of autoimmune encephalopathy that occurs across the lifespan, and disproportionately affects children. In this test-specific episode of the "Answers From the Lab" podcast, Andrew McKeon, M.B., B.Ch., M.D., explains how Mayo Clinic Laboratories' GABA-A receptor antibody assay aids diagnosis of this serious but treatable condition.
Mayo Clinic Laboratories, a leading global reference laboratory, and Progentec Diagnostics, a digital health and biomarker technology-based company focused on autoimmune conditions, today announced a strategic collaboration to bring Progentec’s suite of proprietary biomarker blood tests for the proactive management of autoimmune diseases to market. The collaboration aims to increase accessibility for providers and patients across the U.S. and select global markets.
In this episode of “Answers From the Lab,” host Bobbi Pritt, M.D., chair of the Department of Laboratory Medicine and Pathology at Mayo Clinic, is joined by Vanda Lennon, M.D., Ph.D., founder of the Neuroimmunology Laboratory and now director of the Neuroimmunology Research Laboratory at Mayo Clinic. Dr. Pritt and Dr. Lennon discuss the research and testing innovations that have led to critical advancements in the field of autoimmune neurology over the last few decades.
Tying together the expertise and curiosity of Mayo Clinic autoimmune neurology researchers with eager patients who have rare disease and are looking for answers, the innovative collaboration benefits both patients affected by MOGAD and scientists on the front lines of discovery.
Joe Mondloch and his wife Sue have existed in a grey area of uncertainty due to the unpredictable autoimmune neurological illness Joe has lived with for the last seven years. Rare, incurable, and debilitating, the newly classified disorder can be hard to manage. But thanks to information and direction provided by a rare disease advocacy group, the Mondlochs sought care at Mayo Clinic and received much more than answers.
Sean Pittock, M.D., explains how Mayo Clinic Laboratories' novel Ma2 test aids diagnosis of autoimmune neurology disorders that are often caused by underlying cancer. Rapid diagnosis is key to preventing significant disability and disease.
In this test-specific episode of “Answers From the Lab,” host Bobbi Pritt, M.D., chair of the Department of Laboratory Medicine and Pathology at Mayo Clinic, and Bjorn Oskarsson, M.D., a neurologist at Mayo Clinic’s Florida campus, discuss how the neurofilament light chain test available through Mayo Clinic Laboratories helps physicians diagnose neurological disease and assess neuronal damage.
In this month's "Hot Topic," Eoin Flanagan, M.B., B. Ch., discusses the important issue of autoimmune encephalitis misdiagnosis and identifies red flags that be useful in clinical practice to suggest alternative diagnoses and highlight antibodies that sometimes cause confusion.
PACEIn this month’s “Virtual Lecture” Eoin Flanagan, M.D., B.Ch., reviews how to diagnose autoimmune encephalitis, what to watch that may suggest a different diagnosis, discuss neural autoantibodies interpretation and putting test results into clinical context.
Education on this topic decreases misdiagnosis and the possibility of misinterpreting the comments provided by the reporting laboratories.
Ed Garber spent months in physical and neurological decline while a cohort of care providers and specialists searched for the root cause of his symptoms. That search for answers ended after testing by Mayo Clinic Laboratories gave them the confirmatory diagnosis they needed.